In patients with bladder carcinoma overexpressing EGFR, treatment with an 213Bi-anti-EGFR-MAb-conjugate resulted in satisfactory therapeutic efficacy, showing that in three of 12 patients no signs of carcinoma in situ were present at 3, 30 and 44 months after treatment23. Here, EGFR is linked to in situ carcinoma.